D is for Dementia
17 November 2016 | By Niamh Louise Marriott, Digital Content Producer
D is for Dementia - the next instalment of our daily pharmaceutical alphabet bringing you up to date with all the latest research on Dementia...
List view / Grid view
Articles
Osteomyelitis: How artificial bone grafts are filling the gap
17 November 2016 | By Niamh Louise Marriott, Digital Content Producer
We caught up with Bonesupport's CEO Richard Davies to find out how they're using artificial bone grafts to help sufferers of chronic osteomyelitis...
C is for Cancer Drugs Fund
16 November 2016 | By Niamh Louise Marriott, Digital Content Producer
C is for Cancer Drugs Fund - the next instalment of our daily pharmaceutical alphabet bringing you up to date with all the latest on the Cancer Drugs Fund
B is for Biosimilars
15 November 2016 | By Niamh Louise Marriott, Digital Content Producer
B is for Biosimilar - the next instalment of our daily pharmaceutical alphabet bringing you up to date with all the latest news and research on the subject of biosimilars.
A is for Antibiotics
14 November 2016 | By Niamh Louise Marriott, Digital Content Producer
A is for Antibiotics - the first instalment of our daily pharmaceutical alphabet bringing you up to date with all the latest news and research on the subject of antibiotics.
Coeliac UK ‘welcomes’ NICE’s coeliac guidance – but is it too little, too late?
14 November 2016 | By Norma McGough, Director of Policy, Research & Campaigns, Coeliac UK
Coeliac UK’s Director of Policy, Research & Campaigns, Norma McGough, welcomes NICE’s new quality standards on coeliac disease, which she believes will bring clarity and improvement to diagnosis screening and better access to long term treatment…
Democratising the Data-Driven Medicine revolution
7 November 2016 | By Jurgi Camblong, CEO and co-founder of Sophia Genetics
Sophia Genetics' CEO Jurgi Camblong says genomic data can now diagnose and tailor individual treatments but how do we democratise Data-Driven Medicine?
Open letter warns of the Brexit effect on the UK’s medicines supply chain
4 November 2016 | By Niamh Louise Marriott, Digital Content Producer
European Pharmaceutical Review caught up with HDA's Executive Director Martin Sawer to discuss the letter and how Brexit will affect the industry...
Issue #5 2016 – Digital edition
20 October 2016 | By European Pharmaceutical Review
In this issue: Biosimilars, Informatics, Ingredients, PAT, HPLC, Microbiology, Product Showcase, Regulation, and much more...
Product Showcase 2016
This product showcase features articles from Charles River, Eppendorf Inc. and Eurofins Lancaster Laboratories...
Ingredients In-Depth Focus 2016
In this Ingredients In-Depth Focus: Excipient quality and supplier interchangeability; Interpreting ICH’s evolving residual solvents guideline; Q&A with Meggle...
HPLC In-Depth Focus 2016
In this HPLC In-Depth Focus: Resolving natural compound complexity with multidimensional chromatography; The advantages of temperature elevations in HPLC...
Biosimilars: litigation outlook
In the Foreword article contributed by Consultant David P. Elder in Issue 3, 2016 of European Pharmaceutical Review, entitled ‘Biosimilars: future prospects’, Dr Elder concluded that it is likely that biosimilars will become increasingly established in both Europe and the United States and that in addition to proteins and peptides,…
Security considerations for external research
Intellectual Property (IP) is the lifeblood of the pharmaceutical industry. Without it, there would not be much of a business. Growing research and development globalisation, externalisation, the expansion of electronic data management systems and the lack of consistent global IP enforcement is increasing the capacity of external and internal parties…
At-line swabbing analysis as a process analytical tool
20 October 2016 | By Adeyinka Aina and Chris Edlin, Pharmaceutical Manufacturing Technology Centre
Swabbing is a technique commonly used during pharmaceutical cleaning protocols to ensure that the cleaning process meets both safety and regulatory requirements; this allows for the cleaning process to be subsequently verified and validated1-7.
